$0.43 EPS Expected for Piedmont Office Realty Trust, Inc. (PDM), Pdl Biopharma (PDLI) Shorts Decreased By 7.69%

June 30, 2017 - By Louis Casey

Analysts expect Piedmont Office Realty Trust, Inc. (NYSE:PDM) to report $0.43 EPS on August, 2.They anticipate $0.03 EPS change or 7.50% from last quarter’s $0.4 EPS. PDM’s profit would be $61.66 million giving it 12.20 P/E if the $0.43 EPS is correct. After having $0.45 EPS previously, Piedmont Office Realty Trust, Inc.’s analysts see -4.44% EPS growth. About 57,810 shares traded. Piedmont Office Realty Trust, Inc. (NYSE:PDM) has risen 9.82% since June 30, 2016 and is uptrending. It has underperformed by 6.88% the S&P500.

Pdl Biopharma Incorporated (NASDAQ:PDLI) had a decrease of 7.69% in short interest. PDLI’s SI was 11.63 million shares in June as released by FINRA. Its down 7.69% from 12.60 million shares previously. With 1.63 million avg volume, 7 days are for Pdl Biopharma Incorporated (NASDAQ:PDLI)’s short sellers to cover PDLI’s short positions. The SI to Pdl Biopharma Incorporated’s float is 7.8%. About 236,458 shares traded. PDL BioPharma Inc (NASDAQ:PDLI) has declined 26.03% since June 30, 2016 and is downtrending. It has underperformed by 42.73% the S&P500.

Among 3 analysts covering PDL BioPharma (NASDAQ:PDLI), 1 have Buy rating, 0 Sell and 2 Hold. Therefore 33% are positive. PDL BioPharma had 6 analyst reports since October 16, 2015 according to SRatingsIntel. PiperJaffray maintained PDL BioPharma Inc (NASDAQ:PDLI) rating on Thursday, December 22. PiperJaffray has “Overweight” rating and $4 target. The firm has “Sector Perform” rating given on Friday, October 16 by RBC Capital Markets. The firm has “Sector Perform” rating given on Thursday, November 5 by RBC Capital Markets. RBC Capital Markets maintained the shares of PDLI in report on Tuesday, February 23 with “Sector Perform” rating. RBC Capital Markets maintained PDL BioPharma Inc (NASDAQ:PDLI) rating on Tuesday, February 2. RBC Capital Markets has “Sector Perform” rating and $5 target.

PDL BioPharma, Inc. seeks to provide return for its shareholders by acquiring and managing a portfolio of companies, products, royalty agreements and debt facilities in the biotechnology, pharmaceutical and medical device industries. The company has market cap of $406.52 million. The Company’s divisions include income generating assets and product sales. It has a 27.85 P/E ratio. The income generating assets segment consists of royalties from issued patents in the United States and elsewhere, covering the humanization of antibodies, which it refers to as the Queen et al. patents; notes and other long-term receivables, royalty rights-at fair value and equity investments.

Investors sentiment decreased to 0.93 in 2016 Q4. Its down 0.07, from 1 in 2016Q3. It is negative, as 24 investors sold PDL BioPharma Inc shares while 59 reduced holdings. 27 funds opened positions while 50 raised stakes. 121.99 million shares or 0.93% less from 123.14 million shares in 2016Q3 were reported. Sei Invests Com stated it has 403 shares. State Street reported 4.27 million shares stake. Amp Cap Invsts has invested 0% in PDL BioPharma Inc (NASDAQ:PDLI). Bridgeway holds 0% or 50,000 shares in its portfolio. Envestnet Asset has 0% invested in PDL BioPharma Inc (NASDAQ:PDLI). Css Ltd Liability Co Il holds 8,068 shares or 0% of its portfolio. New Jersey-based Prudential Fin has invested 0% in PDL BioPharma Inc (NASDAQ:PDLI). Hightower Advsrs Ltd Liability Corporation holds 0% of its portfolio in PDL BioPharma Inc (NASDAQ:PDLI) for 13,887 shares. Kcg Incorporated owns 50,765 shares or 0% of their US portfolio. Dekabank Deutsche Girozentrale invested 0% of its portfolio in PDL BioPharma Inc (NASDAQ:PDLI). Vanguard Grp reported 0% stake. Tudor Invest Et Al has 292,400 shares. Wellington Group Inc Llp invested in 0% or 1.59 million shares. Massachusetts-based Panagora Asset Mgmt Inc has invested 0% in PDL BioPharma Inc (NASDAQ:PDLI). Advsrs Asset stated it has 0.01% of its portfolio in PDL BioPharma Inc (NASDAQ:PDLI).

Since March 24, 2017, it had 1 insider buy, and 0 selling transactions for $49,401 activity. Another trade for 25,000 shares valued at $49,401 was bought by GARCIA PETER S.

Among 4 analysts covering Piedmont Office Realty Trust (NYSE:PDM), 0 have Buy rating, 0 Sell and 4 Hold. Therefore 0 are positive. Piedmont Office Realty Trust had 8 analyst reports since September 3, 2015 according to SRatingsIntel. The rating was maintained by Stifel Nicolaus with “Sell” on Tuesday, May 10. The rating was downgraded by Stifel Nicolaus on Monday, December 14 to “Sell”. The rating was downgraded by Robert W. Baird to “Neutral” on Thursday, January 7. The stock has “Neutral” rating by SunTrust on Thursday, September 3. DA Davidson maintained the stock with “Neutral” rating in Tuesday, May 3 report. Stifel Nicolaus upgraded the shares of PDM in report on Monday, January 23 to “Hold” rating.

Since May 24, 2017, it had 0 buys, and 1 sale for $168,758 activity. Moon Laura P sold 7,800 shares worth $168,758.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.